Clinical trials: Migraine Headache
Foramen Ovale, Patent
The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness
The primary objective of this study is to demonstrate the safety and efficacy of the PFX Closure System when utilized for patent foramen ovale (PFO) in patients suffering from cryptogenic stroke (undetermined cause of stroke)…
- Trial name
- NCT00196040
- Testing
- PFX Closure System
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Cierra
Migraine, Migraine With Aura
A Comprehensive Digital Care Program for Migraine Management
This study evaluates the clinical effectiveness of the Enso for Migraine program, a comprehensive digital care program combining an FDA-cleared neuromodulation wearable device (Enso), personalized exercise therapy, and a…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT07642414
- Testing
- Neuromodulation Wearable Device, Migraine Digital Care Program
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Hinge Health, Inc
Healthy
A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling
The purpose of this clinical trial is to learn about the pharmacokinetics and safety of a drug called zavegepant from samples collected using a patient-centric device called Tasso-Plus (for liquid blood sample collection) and…
- Trial name
- NCT05948085
- Testing
- Zavegepant 10 mg IN
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Migraine
MLD10 in the Prevention of Migraine in Adults
This is a double-blind, placebo-controlled, randomized, multi-center study. Subjects agreeing to participate in the study and meet the entry criteria assessed at the screening visit, will begin a 28 day baseline period to confirm…
- Trial name
- NCT02322333
- Testing
- MLD10
- Where
- 9 sites in United States
- Volunteers
- 157 people
- Sponsor
- Pharmalyte Solutions LLC
Episodic Migraine
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
- Trial name
- PROSPECT-1 (NCT05897320)
- Testing
- Eptinezumab
- Where
- 60 sites in United States, Argentina and 9 more
- Volunteers
- 315 people
- Sponsor
- H. Lundbeck A/S
Migraine
Influence of a Dietary Supplement as Treatment of Migraine in Children and Adolescents
Migraine in children and adolescents can be associated with low serum levels of coenzyme q10, the key-enzyme of mitochondrial energy production.During migraine attacks inflammation is an important issue.
- Trial name
- NCT01010711
- Testing
- Migra 3
- Where
- 2 sites in Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Complen Health GmbH
Migraine
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults
The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
- Trial name
- NCT03732638
- Testing
- Rimegepant
- Where
- 93 sites in United States
- Volunteers
- 1,590 people
- Sponsor
- Pfizer
Migraine
Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults
The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT07304518
- Testing
- PRT-064040 nasal spray
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
Migraine
Abortive Treatment of Migraine With the Cefaly® Abortive Program Device
The purpose of this study is to investigate the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack.
- Trial name
- NCT03217968
- Testing
- Cefaly® Abortive Program device
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Cefaly Technology
Migraine Without Aura
Migraine STImulation Crisis of Migraine
Migraine is a neurovascular disease whose prevalence is estimated at almost 20% of the adult population. Currently, there is no treatment for migraine.
- Trial name
- MISTIC (NCT04568252)
- Testing
- Wristband with millimeter wave emission.
- Where
- 6 sites in France
- Volunteers
- 140 people
- Sponsor
- Remedee SA
Migraine
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic migraine.
- Trial name
- NCT05156398
- Testing
- Rimegepant
- Where
- 93 sites in United States, Canada and 5 more
- Volunteers
- 640 people
- Sponsor
- Pfizer
Migraine
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 (monthly TEV-48125 225 mg and TEV-48125 675 mg once over a period of 3 months) compared with placebo for preventive treatment in Episodic…
- Trial name
- NCT03303092
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 357 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Migraine, Episodic Migraine
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Randomized study of two digital therapeutics for the prevention of episodic migraine
- Conditions
- Migraine, Episodic Migraine, Headache, Headache, Migraine
- Trial name
- ReMMi-D (NCT05853900)
- Testing
- ReMMi-D Digital Therapeutic
- Where
- United States
- Volunteers
- 568 people
- Sponsor
- Click Therapeutics, Inc.
Migraine
Occipital Nerve Stimulation in the Treatment of Migraine
The objective of this proof-of-concept study is to generate initial safety and effectiveness data for the neuro-modulation stimulation (NMS) E-Box in patients with chronic migraine in an acute setting.
- Trial name
- Verona (NCT01855672)
- Testing
- Stimulation of the Occipital Nerves
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Ethicon, Inc.
Migraine, Without Aura
TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)
This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.
- Trial name
- NCT00387881
- Testing
- sumatriptan succinate / naproxen sodium
- Where
- 70 sites in United States
- Volunteers
- 679 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline) as headache prophylaxis in adolescents (children 12 to 17) with chronic migraine.
- Trial name
- NCT01662492
- Testing
- Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2
- Where
- 22 sites in United States
- Volunteers
- 125 people
- Sponsor
- Allergan
Migraine
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
- Trial name
- NCT06603623
- Testing
- BHV-2100
- Where
- 60 sites in United States
- Volunteers
- 647 people
- Sponsor
- Biohaven Therapeutics Ltd.
Migraine Disorders
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
- Trial name
- PROMISE 1 (NCT02559895)
- Testing
- ALD403
- Where
- 87 sites in United States, Georgia
- Volunteers
- 898 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
This is a 60 week study including a double-blind phase followed by an open-label extension phase.
- Trial name
- NCT00156910
- Testing
- Botulinum Toxin Type A
- Where
- 2 sites in United States, Canada
- Volunteers
- 679 people
- Sponsor
- Allergan
Sleep Bruxism, Tension Headache
Treatment Sleep Bruxism With the Luco Hybrid OSA Appliance
To determine the effectiveness of the Luco Hybrid OSA Appliance in the treatment of sleep bruxism and to aid in the treatment of associated tension/migraine type headaches in adults.
- Conditions
- Sleep Bruxism, Tension Headache, Migraine Headache
- Trial name
- LucoHybrid (NCT02882880)
- Testing
- The Luco Hybrid OSA Appliance
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Luco Hybrid OSA Appliance Inc.